If so, application of an ARBs like losartan that enhances circulating ACE1 and ACE2 activities might mitigate SARS virus infection by modulating angiotensin II-stimulated IL-6 induced inflammation, and reducing circulating angiotensin II levels and enabling more AT2-receptor stimulation [2, 17].∗ Nevertheless, angiotensin II-AT1-receptor blockade will not prevent virus invasion. Here, ACE2 is linked to viral infectious disease.